Fundraising Fox
Spero Therapeutics
NASDAQ: SPROCambridge, US · Founded 2013 · Delaware corporation · 45 employees on LinkedIn · 8 known investors
Find your way into Spero Therapeutics
Sign up to see every warm intro you have to Spero Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Spero Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
Founders & leadership
Spero Therapeutics was founded in 2013 by Ankit Mahadevia.
Board
Investors · 8
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: MRL Ventures Fund's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: press coverage · funding news · Not right? Tell us
How we know: the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$92.2M disclosed across 3 of 4 rounds · 2017–2026
▶$9MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
- Milind DeshpandeDirector
- Kamal HamedExecutive Officer
- Scott JacksonDirector
- Tamara JosephExecutive Officer
- Kathleen TregoningDirector
- Patrick VinkDirector
- Satyavrat ShuklaExecutive Officer
- Timothy KeutzerExecutive Officer
- John C. Pottage, Jr.Director
- Ankit MahadeviaExecutive Officer, Director
- Cynthia SmithDirector
- Frank E. ThomasDirector
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedJul 2021 · 1 investors · BiotechnologyRule 506(b)
- Milind DeshpandeDirector
- David MelnickExecutive Officer
- Patrick VinkDirector
- Cynthia SmithDirector
- Satyavrat ShuklaExecutive Officer
- Tamara JosephExecutive Officer
- Scott JacksonDirector
- Timothy KeutzerExecutive Officer
- Frank E. ThomasDirector
- Cristina LarkinExecutive Officer
- John C. Pottage, Jr.Director
- Ankit MahadeviaExecutive Officer, Director
- Jean-Francois FormelaDirector
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$43.2MraisedMar 2017 · 11 investors · BiotechnologyRule 506(b)
- Patrick VinkDirector
- Milind DeshpandeDirector
- Jean-Francois FormelaDirector
- Reza HalseDirector
- Casper BreumDirector
- Ankit MahadeviaExecutive Officer, Director
- Stephen GarbaczExecutive Officer
- Vikas GoyalDirector
- Offering amount
- $43.2M
- Amount sold
- $43.2M
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Spero Therapeutics went on to found or lead other companies.
Related companies · 4
Companies working in the same space as Spero Therapeutics.
In the news
Frequently asked questions
- What does Spero Therapeutics do?
- Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
- Who founded Spero Therapeutics?
- Spero Therapeutics was founded by Ankit Mahadevia in 2013.
- Who are Spero Therapeutics's investors?
- Spero Therapeutics's investors include GV (Google Ventures), HEALTHCARE ROYALTY PARTNERS, MRL Ventures Fund, OUP (Osage University Partners), RA Capital, Alphabet, Atlas Venture, Fidelity Investments.
- How much funding has Spero Therapeutics raised?
- Spero Therapeutics has disclosed $92.2M raised across 3 of its 4 known rounds.
- Where is Spero Therapeutics headquartered?
- Spero Therapeutics is headquartered in Cambridge, US.